Global Human Growth Hormone Deficiency (GHD) Drugs Market Assessment: Current Market, Pipeline Review, Clinical Trials, Market Potential – Forecast to 2023
EXECUTIVE SUMMARY
The report presents the market potential of four major pipeline drugs (TransCon-hGH, Somapacitan, Somavaratan, Somatrogonmeant) for the treatment of human Growth Hormone Deficiency (GHD). These four drugs that fall in the various categories of paediatrics and adults by end user have been recognized as being clinically effective in human Growth Hormone Deficiency treatment. Expected to be launched in the market within the next 4-5 years, these four potential drugs are likely to bring about major changes in the way Growth Hormone Deficiency is treated globally.
A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global human Growth Hormone Deficiency (GHD) Pipeline Drugs Market by assessing the potential of the four drugs that will be launched in the near future. Also, the report assesses the results of various clinical trials undertaken for each of the four drugs, the product profile, description and regulatory phase of each of the four drugs. Also, 7Ps Analysis (Patent, Phase, Pathway, Patient, Physician, Payer, Partner) has been done for each of the four drugs to present the current perspective.
The report titled “Global Human Growth Hormones Deficiency (GHD) Drugs Market Assessment: Current Market, Pipeline Review, Clinical Trials, Market Potential – Forecast to 2023” also analyzes the overall sizing, growth and forecast of Growth Hormone Deficiency Drugs Market for the global market.
Over the recent years, the human Growth Hormone Deficiency Drugs market is growing rapidly due to rising prevalence of patients with Growth Hormone Deficiency (GHD) around the world. Globally, the growth of human Growth Hormone Deficiency Drugs market is driven by increased penetration of drugs by market players coupled with introduction of new drugs with improved patient compliance.
The global human Growth Hormone Deficiency (GHD) Pipeline Drugs Market is projected to display a robust growth during 2018 – 2023, chiefly driven by low efficacy and poor dosing schedules of present drugs and improved safety and efficacy of investigational drugs. The report has covered and analysed the present human Growth Hormone Deficiency (GHD) drugs in the market and has also analysed potential of four major pipeline drugs. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation.
SCOPE OF THE REPORT
Global human Growth Hormone Deficiency (GHD) Pipeline Drugs Assessment – TransCon-hGH, Somapacitan, Somavaratan, Somatrogon (Forecast Period: 2020-2023)
The report could be customized according to the client’s specific research requirements. No additional cost will be required to pay for limited additional research.
The report presents the market potential of four major pipeline drugs (TransCon-hGH, Somapacitan, Somavaratan, Somatrogonmeant) for the treatment of human Growth Hormone Deficiency (GHD). These four drugs that fall in the various categories of paediatrics and adults by end user have been recognized as being clinically effective in human Growth Hormone Deficiency treatment. Expected to be launched in the market within the next 4-5 years, these four potential drugs are likely to bring about major changes in the way Growth Hormone Deficiency is treated globally.
A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global human Growth Hormone Deficiency (GHD) Pipeline Drugs Market by assessing the potential of the four drugs that will be launched in the near future. Also, the report assesses the results of various clinical trials undertaken for each of the four drugs, the product profile, description and regulatory phase of each of the four drugs. Also, 7Ps Analysis (Patent, Phase, Pathway, Patient, Physician, Payer, Partner) has been done for each of the four drugs to present the current perspective.
The report titled “Global Human Growth Hormones Deficiency (GHD) Drugs Market Assessment: Current Market, Pipeline Review, Clinical Trials, Market Potential – Forecast to 2023” also analyzes the overall sizing, growth and forecast of Growth Hormone Deficiency Drugs Market for the global market.
Over the recent years, the human Growth Hormone Deficiency Drugs market is growing rapidly due to rising prevalence of patients with Growth Hormone Deficiency (GHD) around the world. Globally, the growth of human Growth Hormone Deficiency Drugs market is driven by increased penetration of drugs by market players coupled with introduction of new drugs with improved patient compliance.
The global human Growth Hormone Deficiency (GHD) Pipeline Drugs Market is projected to display a robust growth during 2018 – 2023, chiefly driven by low efficacy and poor dosing schedules of present drugs and improved safety and efficacy of investigational drugs. The report has covered and analysed the present human Growth Hormone Deficiency (GHD) drugs in the market and has also analysed potential of four major pipeline drugs. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation.
SCOPE OF THE REPORT
Global human Growth Hormone Deficiency (GHD) Pipeline Drugs Assessment – TransCon-hGH, Somapacitan, Somavaratan, Somatrogon (Forecast Period: 2020-2023)
- Market Potential
- Clinical Trials
- Product Description
- Regulatory Phases
- 7Ps Analysis
- Actual Period: 2013-2017
- Forecast Period: 2018-2023
- Actual Period: 2013-2017
- Forecast Period: 2018-2023
- Actual Period: 2013-2017
- Forecast Period: 2018-2023
- Company Analysis – Ascendis Pharma A/S, Novo Nordisk A/S, Versartis Inc., Opko Health Inc., Pfizer Inc.
The report could be customized according to the client’s specific research requirements. No additional cost will be required to pay for limited additional research.
1. RESEARCH METHODOLOGY
2. EXECUTIVE SUMMARY
3. GROWTH HORMONE DEFICIENCY DRUGS PRODUCT - AN OVERVIEW
3.1. Growth Hormone (GH) and its Function
3.2. Growth Hormone Deficiency (GHD) and its Symptoms
3.3. Causes of Growth Hormone Deficiency (GHD)
4. DIAGNOSIS OF GROWTH HORMONE DEFICIENCY (GHD)
5. TREATMENT OF GROWTH HORMONE DEFICIENCY (GHD)
6. GLOBAL GROWTH HORMONE DRUGS MARKET
6.1. Global Growth Hormone Drugs Market Size, By value, 2013-2017
6.2. Global Growth Hormone Drugs Market Size, By value, 2018-2023
7. GLOBAL GROWTH HORMONE DEFICIENCY DRUGS MARKET
7.1. Global Growth Hormone Deficiency Drugs Market Size, By value, 2013-2017
7.2. Global Growth Hormone Deficiency Drugs Market Size, By value, 2018-2023
8. GLOBAL GROWTH HORMONE DEFICIENCY DRUGS MARKET, BY END USER
8.1. Global Growth Hormone Deficiency Drugs Market, By End User: Break down (%)
8.1.1. Global Growth Hormone Deficiency Drugs Market, By End User: 2017%
8.1.2. Global Growth Hormone Deficiency Drugs Market, By End User: 2023%
8.2. Global Growth Hormone Deficiency Drugs Market, By End User – By Pediatrics
8.2.1. By Value (2013 – 2017)
8.2.2. By Value (2018 – 2023)
8.3. Global Growth Hormone Deficiency Drugs Market, By End User – By Adult
8.3.1. By Value (2013 – 2017)
8.3.2. By Value (2018 – 2023)
9. GLOBAL GROWTH HORMONE DEFICIENCY DRUGS MARKET: REGIONAL ANALYSIS
9.1. North America Growth Hormone Deficiency Drugs Market
9.1.1. By Value (2013 – 2017)
9.1.2. By Value (2018 – 2023)
9.2. Europe Growth Hormone Deficiency Drugs Market
9.2.1. By Value (2013 – 2017)
9.2.2. By Value (2018 – 2023)
9.3. ROW Growth Hormone Deficiency Drugs Market
9.3.1. By Value (2013 – 2017)
9.3.2. By Value (2018 – 2023)
10. GLOBAL GROWTH HORMONE DEFICIENCY DRUGS MARKET: COUNTRY ANALYSIS
10.1. U.S. Growth Hormone Deficiency Drugs Market
10.1.1. By Value (2013 – 2017)
10.1.2. By Value (2018 – 2023)
10.2. U.K. Growth Hormone Deficiency Drugs Market
10.2.1. By Value (2013 – 2017)
10.2.2. By Value (2018 – 2023)
10.3. France Growth Hormone Deficiency Drugs Market
10.3.1. By Value (2013 – 2017)
10.3.2. By Value (2018 – 2023)
10.4. Germany Growth Hormone Deficiency Drugs Market
10.4.1. By Value (2013 – 2017)
10.4.2. By Value (2018 – 2023)
10.5. Spain Growth Hormone Deficiency Drugs Market
10.5.1. By Value (2013 – 2017)
10.5.2. By Value (2018 – 2023)
10.6. Japan Growth Hormone Deficiency Drugs Market
10.6.1. By Value (2013 – 2017)
10.6.2. By Value (2018 – 2023)
11. HUMAN GROWTH HORMONE DEFICIENCY (HGHD) PIPELINE DRUGS COVERAGE
11.1. hGHD Pipeline Drugs – TransCon-hGH
11.1.1. Description
11.1.2. Regulatory Milestones
11.1.3. Advantages & Disadvantages
11.1.4. Product Profile & Launch Date
11.1.5. Clinical Trials and Status
11.1.6. Pivotal Clinical Trials and Results
11.1.7. TransCon-hGH – Global Market Potential
11.1.8. TransCon-hGH – Global Market Potential
11.2. hGHD Pipeline Drugs – Somapacitan
11.2.1. Description
11.2.2. Regulatory Milestones
11.2.3. Advantages & Disadvantages
11.2.4. Product Profile & Launch Date
11.2.5. Clinical Trials and Status
11.2.6. Pivotal Clinical Trials and Results
11.2.7. Somapacitan – Global Market Potential
11.2.8. Somapacitan – 7Ps Analysis
11.3. hGHD Pipeline Drugs – Somavaratan
11.3.1. Description
11.3.2. Regulatory Milestones
11.3.3. Advantages & Disadvantages
11.3.4. Product Profile & Launch Date
11.3.5. Clinical Trials and Status
11.3.6. Pivotal Clinical Trials and Results
11.3.7. Somavaratan – Global Market Potential
11.3.8. Somavaratan – 7Ps Analysis
11.4. hGHD Pipeline Drugs – Somatrogon/ Lagova
11.4.1. Description
11.4.2. Regulatory Milestones
11.4.3. Advantages & Disadvantages
11.4.4. Product Profile & Launch Date
11.4.5. Clinical Trials and Status
11.4.6. Pivotal Clinical Trials and Results
11.4.7. Somatrogon/ Lagova – Global Market Potential
11.4.8. Somatrogon/ Lagova – 7Ps Analysis
11.5. Competitive Landscape
12. COMPANY PROFILES
12.1. Ascendis Pharma A/S
12.2. Novo Nordisk A/S
12.3. Versartis Inc.
12.4. Opko Health, Inc.
12.5. Pfizer Inc
2. EXECUTIVE SUMMARY
3. GROWTH HORMONE DEFICIENCY DRUGS PRODUCT - AN OVERVIEW
3.1. Growth Hormone (GH) and its Function
3.2. Growth Hormone Deficiency (GHD) and its Symptoms
3.3. Causes of Growth Hormone Deficiency (GHD)
4. DIAGNOSIS OF GROWTH HORMONE DEFICIENCY (GHD)
5. TREATMENT OF GROWTH HORMONE DEFICIENCY (GHD)
6. GLOBAL GROWTH HORMONE DRUGS MARKET
6.1. Global Growth Hormone Drugs Market Size, By value, 2013-2017
6.2. Global Growth Hormone Drugs Market Size, By value, 2018-2023
7. GLOBAL GROWTH HORMONE DEFICIENCY DRUGS MARKET
7.1. Global Growth Hormone Deficiency Drugs Market Size, By value, 2013-2017
7.2. Global Growth Hormone Deficiency Drugs Market Size, By value, 2018-2023
8. GLOBAL GROWTH HORMONE DEFICIENCY DRUGS MARKET, BY END USER
8.1. Global Growth Hormone Deficiency Drugs Market, By End User: Break down (%)
8.1.1. Global Growth Hormone Deficiency Drugs Market, By End User: 2017%
8.1.2. Global Growth Hormone Deficiency Drugs Market, By End User: 2023%
8.2. Global Growth Hormone Deficiency Drugs Market, By End User – By Pediatrics
8.2.1. By Value (2013 – 2017)
8.2.2. By Value (2018 – 2023)
8.3. Global Growth Hormone Deficiency Drugs Market, By End User – By Adult
8.3.1. By Value (2013 – 2017)
8.3.2. By Value (2018 – 2023)
9. GLOBAL GROWTH HORMONE DEFICIENCY DRUGS MARKET: REGIONAL ANALYSIS
9.1. North America Growth Hormone Deficiency Drugs Market
9.1.1. By Value (2013 – 2017)
9.1.2. By Value (2018 – 2023)
9.2. Europe Growth Hormone Deficiency Drugs Market
9.2.1. By Value (2013 – 2017)
9.2.2. By Value (2018 – 2023)
9.3. ROW Growth Hormone Deficiency Drugs Market
9.3.1. By Value (2013 – 2017)
9.3.2. By Value (2018 – 2023)
10. GLOBAL GROWTH HORMONE DEFICIENCY DRUGS MARKET: COUNTRY ANALYSIS
10.1. U.S. Growth Hormone Deficiency Drugs Market
10.1.1. By Value (2013 – 2017)
10.1.2. By Value (2018 – 2023)
10.2. U.K. Growth Hormone Deficiency Drugs Market
10.2.1. By Value (2013 – 2017)
10.2.2. By Value (2018 – 2023)
10.3. France Growth Hormone Deficiency Drugs Market
10.3.1. By Value (2013 – 2017)
10.3.2. By Value (2018 – 2023)
10.4. Germany Growth Hormone Deficiency Drugs Market
10.4.1. By Value (2013 – 2017)
10.4.2. By Value (2018 – 2023)
10.5. Spain Growth Hormone Deficiency Drugs Market
10.5.1. By Value (2013 – 2017)
10.5.2. By Value (2018 – 2023)
10.6. Japan Growth Hormone Deficiency Drugs Market
10.6.1. By Value (2013 – 2017)
10.6.2. By Value (2018 – 2023)
11. HUMAN GROWTH HORMONE DEFICIENCY (HGHD) PIPELINE DRUGS COVERAGE
11.1. hGHD Pipeline Drugs – TransCon-hGH
11.1.1. Description
11.1.2. Regulatory Milestones
11.1.3. Advantages & Disadvantages
11.1.4. Product Profile & Launch Date
11.1.5. Clinical Trials and Status
11.1.6. Pivotal Clinical Trials and Results
11.1.7. TransCon-hGH – Global Market Potential
11.1.8. TransCon-hGH – Global Market Potential
11.2. hGHD Pipeline Drugs – Somapacitan
11.2.1. Description
11.2.2. Regulatory Milestones
11.2.3. Advantages & Disadvantages
11.2.4. Product Profile & Launch Date
11.2.5. Clinical Trials and Status
11.2.6. Pivotal Clinical Trials and Results
11.2.7. Somapacitan – Global Market Potential
11.2.8. Somapacitan – 7Ps Analysis
11.3. hGHD Pipeline Drugs – Somavaratan
11.3.1. Description
11.3.2. Regulatory Milestones
11.3.3. Advantages & Disadvantages
11.3.4. Product Profile & Launch Date
11.3.5. Clinical Trials and Status
11.3.6. Pivotal Clinical Trials and Results
11.3.7. Somavaratan – Global Market Potential
11.3.8. Somavaratan – 7Ps Analysis
11.4. hGHD Pipeline Drugs – Somatrogon/ Lagova
11.4.1. Description
11.4.2. Regulatory Milestones
11.4.3. Advantages & Disadvantages
11.4.4. Product Profile & Launch Date
11.4.5. Clinical Trials and Status
11.4.6. Pivotal Clinical Trials and Results
11.4.7. Somatrogon/ Lagova – Global Market Potential
11.4.8. Somatrogon/ Lagova – 7Ps Analysis
11.5. Competitive Landscape
12. COMPANY PROFILES
12.1. Ascendis Pharma A/S
12.2. Novo Nordisk A/S
12.3. Versartis Inc.
12.4. Opko Health, Inc.
12.5. Pfizer Inc
LIST OF FIGURES
Figure 1: Global Growth Hormones Drugs Market Size, By value, 2013-2017 (USD Billion)
Figure 2: Global Growth Hormones Drugs Market Size, By value, 2018-2023 (USD Billion)
Figure 3: Global Growth Hormones Market Share 2017
Figure 4: Sales of Growth Hormones, By Value, 2014-2017
Figure 5: Global Growth Hormone Market Share, 2017 (%)
Figure 6: Global Growth Hormones Deficiency Drugs Market Size, By value, 2013-2017 (USD Billion)
Figure 7: Global Growth Hormones Deficiency Drugs Market Size, By value, 2018-2023 (USD Billion)
Figure 8: Global Growth Hormone Market 2017
Figure 9: Global Growth Hormone Market 2028
Figure 10: Global Growth Hormone Deficiency Drugs Market Share, By End User, 2017 (%)
Figure 11: Global Growth Hormone Deficiency Drugs Market Share, By End User, 2023 (%)
Figure 12: Global Growth Hormone Deficiency Drugs Market, By Pediatrics, By Value, 2013-2017 (USD Billion)
Figure 13: Global Growth Hormone Deficiency Drugs Market, By Pediatrics, By Value, 2018-2023 (USD Billion)
Figure 14: Global Growth Hormone Deficiency Drugs Market, By Adults, By Value, 2013-2017 (USD Billion)
Figure 15: Global Growth Hormone Deficiency Drugs Market, By Adults, By Value, 2018-2023 (USD Billion)
Figure 16: North America Growth Hormone Deficiency Drugs Market Size, By value, 2013-2023 (USD Billion)
Figure 17: Europe Growth Hormone Deficiency Drugs Market Size, By value, 2013-2023 (USD Billion)
Figure 18: ROW Growth Hormone Deficiency Drugs Market Size, By value, 2013-2023 (USD Billion)
Figure 19: US Growth Hormone Deficiency Drugs Market Size, By value, 2013-2023 (USD Billion)
Figure 20: U.S. Per Capita Health Expenditure, 2012-2016 (USD)
Figure 21: U.S Prevalence of Cancer, in cases per 100,000 (2014-2016)
Figure 22: UK Growth Hormone Deficiency Drugs Market Size, By value, 2013-2023 (USD Billion)
Figure 23: France Growth Hormone Deficiency Drugs Market Size, By value, 2013-2023 (USD Billion)
Figure 24: France Per Capita Healthcare Expenditure (USD)
Figure 25: France Prevalence of Cancer, in cases per 100,000 (2014-2016)
Figure 26: Germany Growth Hormone Deficiency Drugs Market Size, By value, 2013-2023 (USD Billion)
Figure 27: Germany Healthcare Expenditure (USD Billion, 2014-2017
Figure 28: Germany Prevalence of Cancer, in cases per 100,000 (2014-2016)
Figure 29: Spain Growth Hormone Deficiency Drugs Market Size, By value, 2013-2023 (USD Billion)
Figure 30: Japan Growth Hormone Deficiency Drugs Market Size, By value, 2013-2023 (USD Billion)
Figure 31: Annualized Height Velocity (Mean + SD) of full dataset of 53 patients after 6 months of treatment
Figure 32: Change in HT SDS (Mean + SD) of full dataset of 53 patients after 6 months of treatment
Figure 33: Dose Proportional IGF-1 Elevation Observed into the Normal Range
Figure 34: Comparable hGH levels for TransCon Growth Hormone and Daily hGH
Figure 35: Global TransCon hGH Market Size, By Value, Forecast, 2020-2023 (USD million)
Figure 36: Annualized Height Velocity (Mean + SD) of full dataset of 53 patients after 6 months of treatment
Figure 37: Global Somapacitan (NN8640) Market Size, By Value, Forecast, 2020-2023 (USD million)
Figure 38: Height Velocity at 12 months in ITT and PP groups
Figure 39: Global Somavaratan (VRS-317) Market Size, By Value, Forecast, 2020-2023 (USD million)
Figure 40: Mean annualized HV for subjects completed 24 month of once weekly Somatrogon treatment
Figure 41: Mean annualized HV for subjects completed 24 month of once weekly Somatrogon treatment
Figure 42: Global Somatrogon (Lagova) Market Size, By Value, Forecast, 2020-2023 (USD million)
Figure 43: Ascendis Pharma Company Net Sales, By Value, in million €
Figure 44: Novo Nordisk Company Net Sales, By Value, in million DKK
Figure 45: Norditropin® net sales, by value, in million DKK
Figure 46: Pfizer Company Revenue, By Value, in million USD
Figure 47: Genotropin net sales, by value, in million USD
Figure 1: Global Growth Hormones Drugs Market Size, By value, 2013-2017 (USD Billion)
Figure 2: Global Growth Hormones Drugs Market Size, By value, 2018-2023 (USD Billion)
Figure 3: Global Growth Hormones Market Share 2017
Figure 4: Sales of Growth Hormones, By Value, 2014-2017
Figure 5: Global Growth Hormone Market Share, 2017 (%)
Figure 6: Global Growth Hormones Deficiency Drugs Market Size, By value, 2013-2017 (USD Billion)
Figure 7: Global Growth Hormones Deficiency Drugs Market Size, By value, 2018-2023 (USD Billion)
Figure 8: Global Growth Hormone Market 2017
Figure 9: Global Growth Hormone Market 2028
Figure 10: Global Growth Hormone Deficiency Drugs Market Share, By End User, 2017 (%)
Figure 11: Global Growth Hormone Deficiency Drugs Market Share, By End User, 2023 (%)
Figure 12: Global Growth Hormone Deficiency Drugs Market, By Pediatrics, By Value, 2013-2017 (USD Billion)
Figure 13: Global Growth Hormone Deficiency Drugs Market, By Pediatrics, By Value, 2018-2023 (USD Billion)
Figure 14: Global Growth Hormone Deficiency Drugs Market, By Adults, By Value, 2013-2017 (USD Billion)
Figure 15: Global Growth Hormone Deficiency Drugs Market, By Adults, By Value, 2018-2023 (USD Billion)
Figure 16: North America Growth Hormone Deficiency Drugs Market Size, By value, 2013-2023 (USD Billion)
Figure 17: Europe Growth Hormone Deficiency Drugs Market Size, By value, 2013-2023 (USD Billion)
Figure 18: ROW Growth Hormone Deficiency Drugs Market Size, By value, 2013-2023 (USD Billion)
Figure 19: US Growth Hormone Deficiency Drugs Market Size, By value, 2013-2023 (USD Billion)
Figure 20: U.S. Per Capita Health Expenditure, 2012-2016 (USD)
Figure 21: U.S Prevalence of Cancer, in cases per 100,000 (2014-2016)
Figure 22: UK Growth Hormone Deficiency Drugs Market Size, By value, 2013-2023 (USD Billion)
Figure 23: France Growth Hormone Deficiency Drugs Market Size, By value, 2013-2023 (USD Billion)
Figure 24: France Per Capita Healthcare Expenditure (USD)
Figure 25: France Prevalence of Cancer, in cases per 100,000 (2014-2016)
Figure 26: Germany Growth Hormone Deficiency Drugs Market Size, By value, 2013-2023 (USD Billion)
Figure 27: Germany Healthcare Expenditure (USD Billion, 2014-2017
Figure 28: Germany Prevalence of Cancer, in cases per 100,000 (2014-2016)
Figure 29: Spain Growth Hormone Deficiency Drugs Market Size, By value, 2013-2023 (USD Billion)
Figure 30: Japan Growth Hormone Deficiency Drugs Market Size, By value, 2013-2023 (USD Billion)
Figure 31: Annualized Height Velocity (Mean + SD) of full dataset of 53 patients after 6 months of treatment
Figure 32: Change in HT SDS (Mean + SD) of full dataset of 53 patients after 6 months of treatment
Figure 33: Dose Proportional IGF-1 Elevation Observed into the Normal Range
Figure 34: Comparable hGH levels for TransCon Growth Hormone and Daily hGH
Figure 35: Global TransCon hGH Market Size, By Value, Forecast, 2020-2023 (USD million)
Figure 36: Annualized Height Velocity (Mean + SD) of full dataset of 53 patients after 6 months of treatment
Figure 37: Global Somapacitan (NN8640) Market Size, By Value, Forecast, 2020-2023 (USD million)
Figure 38: Height Velocity at 12 months in ITT and PP groups
Figure 39: Global Somavaratan (VRS-317) Market Size, By Value, Forecast, 2020-2023 (USD million)
Figure 40: Mean annualized HV for subjects completed 24 month of once weekly Somatrogon treatment
Figure 41: Mean annualized HV for subjects completed 24 month of once weekly Somatrogon treatment
Figure 42: Global Somatrogon (Lagova) Market Size, By Value, Forecast, 2020-2023 (USD million)
Figure 43: Ascendis Pharma Company Net Sales, By Value, in million €
Figure 44: Novo Nordisk Company Net Sales, By Value, in million DKK
Figure 45: Norditropin® net sales, by value, in million DKK
Figure 46: Pfizer Company Revenue, By Value, in million USD
Figure 47: Genotropin net sales, by value, in million USD
LIST OF TABLES
Table A: Upcoming Drugs in the market of Growth Hormone Deficiency and their Clinical Status from 2016 - 2020
Table A: Upcoming Drugs in the market of Growth Hormone Deficiency and their Clinical Status from 2016 - 2020
